Ashwin Patel
With a Master’s degree in Pharmaceutical Sciences from St. John’s University, New York, I bring a strong foundation in science, innovation, and critical analysis to the pharmaceutical industry. As an entrepreneur and science communicator, my mission is to bridge the gap between complex pharma developments and public understanding through credible, insightful news. Combining academic expertise with a passion for advancing healthcare knowledge, I founded this platform to deliver timely and accurate pharmaceutical news, empowering professionals, researchers, and curious minds alike.
Uncategorized
Roche’s Tecentriq Halves Recurrence, Death Risk in Stage 3 dMMR Colon Cancer
The Roche Tecentriq colon cancer Phase 3 trial reveals a striking 50% decrease in recurrence and mortality among stage 3 dMMR patients when added to chemotherapy—potentially reshaping adjuvant treatment protocols.
Healthcare
South Africa Ramps Up Vaccinations as Foot-and‑Mouth Disease Spreads Across Provinces
The South Africa foot-and-mouth disease outbreak has extended to five provinces, prompting authorities to order over 900,000 vaccine doses and consider disaster-level response. Quarantine in major feedlots and export bans threaten the country’s cattle sector and beef exports.
Healthcare
U.S. COVID Vaccine Recommendations Cause Confusion Among Doctors and Insurers
The recent shifts in U.S. COVID vaccine recommendations by Health Secretary RFK Jr. and CDC have created confusion over who should get boosters and what insurers cover, especially for children and pregnant women. With insurers awaiting ACIP guidance ahead of the late‑June meeting, the healthcare system braces for uncertainty.
Healthcare
Brazil Bird Flu Case Ruled Out at Commercial Farm: Signs of Strong Containment
Brazil bird flu case ruled out at a commercial chicken farm in Rio Grande do Sul after extensive testing. With only one confirmed farm outbreak and strong biosecurity, the poultry sector braces for renewed exports and industry-wide resilience.
All News
Ozempic Wegovy Eye Risk: EMA Confirms Rare NAION Side Effect
The European Medicines Agency has confirmed a rare but serious Ozempic Wegovy eye risk—non-arteritic anterior ischemic optic neuropathy (NAION). Semaglutide users should be alert to vision changes and consult doctors promptly.
Innovation
AI-Powered Radiology Service Launched to Transform Cancer Detection in NHS
The new AI‑powered radiology service integrates machine learning with medical imaging across NHS sites to enhance cancer detection—from sarcoma to prostate tumors—accelerating diagnosis and empowering clinicians with reliable, AI‑driven insights.
Clinical Trials
Zepbound vs Wegovy Head-to-Head Trial: A New Benchmark in Obesity Treatment
In a landmark 72-week clinical trial, Eli Lilly's Zepbound achieved significantly greater weight loss compared to Novo Nordisk's Wegovy, marking a pivotal advancement in obesity pharmacotherapy.
All News
Accropeutics AC-201 Phase 2 Trial Shows Strong Efficacy in Psoriasis Treatment
Accropeutics’ oral TYK2/JAK1 inhibitor AC-201 has shown major efficacy in a Phase 2 trial for moderate-to-severe plaque psoriasis. The study indicates significant clinical improvements and a favorable safety profile, potentially reshaping autoimmune treatment standards.
Join our community of SUBSCRIBERS and be part of the conversation.
To subscribe, simply enter your email address on our website or click the subscribe button below. Don't worry, we respect your privacy and won't spam your inbox. Your information is safe with us.